[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100544040":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":31,"centralContacts":36,"locations":41,"responsibleParty":78,"collaborators":22,"id":80,"slug":22,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":22,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":22,"enrollmentInfo":88,"targetDuration":22,"studyType":91,"phases":92,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":100,"whyStopped":22,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":110},{"fullName":5,"class":6},"Zhongnan Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Tislelizumab+Carboplatin+Paclitaxel","EXPERIMENTAL","Tislelizumab 200mg D1 +Carboplatin(AUC=5) D1+Paclitaxel(175 mg\u002Fm2 ) D1, every 3 weeks (21 days) is a treatment cycle",[13,14,15],"Drug: Tislelizumab","Drug: Paclitaxel","Drug: Carboplatin",[17,23,27],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":22},"DRUG","Tislelizumab","Tislelizumab 200mg D1 ,Q3W",[9],null,{"type":18,"name":24,"description":25,"armGroupLabels":26,"otherNames":22},"Paclitaxel","Paclitaxel(175 mg\u002Fm2 ) D1,Q3W",[9],{"type":18,"name":28,"description":29,"armGroupLabels":30,"otherNames":22},"Carboplatin","Carboplatin(AUC=5) D1,Q3W",[9],[32],{"name":33,"affiliation":34,"role":35},"Zheng Hu, MD,PhD","Wuhan University","PRINCIPAL_INVESTIGATOR",[37],{"name":33,"role":38,"phone":39,"phoneExt":22,"email":40},"CONTACT","13632120686","Huzheng1988@163.com",[42,59,67],{"facility":43,"status":22,"city":44,"state":45,"zip":46,"country":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"The Central Hospital of Wuhan","Wuhan","Hubei","430014","China",{"type":49,"coordinates":50},"Point",[51,52],114.26667,30.58333,{"lat":52,"lon":51},[55],{"name":56,"role":38,"phone":57,"phoneExt":22,"email":58},"Xun Tian, MD,PhD","15327205656","tianxun@126.com",{"facility":60,"status":22,"city":44,"state":45,"zip":61,"country":47,"cosmosGeoPoint":62,"geoPoint":64,"contacts":65},"Zhongnan Hospital of Wuhan University","430062",{"type":49,"coordinates":63},[51,52],{"lat":52,"lon":51},[66],{"name":33,"role":38,"phone":39,"phoneExt":22,"email":40},{"facility":68,"status":22,"city":44,"state":45,"zip":69,"country":47,"cosmosGeoPoint":70,"geoPoint":72,"contacts":73},"Hubei maternal and child health care hospital","430070",{"type":49,"coordinates":71},[51,52],{"lat":52,"lon":51},[74],{"name":75,"role":38,"phone":76,"phoneExt":22,"email":77},"QuanFu Ma, MD,PhD","13728133014","dm626925@126.com",{"type":79,"investigatorFullName":22,"investigatorTitle":22,"investigatorAffiliation":22,"oldNameTitle":22,"oldOrganization":22},"SPONSOR","100544040",false,"NCT06363708","Tislelizumab in Combination With Chemotherapy as a Neoadjuvant Treatment for Advanced Endometrial Cancer","Tislelizumab Combined With Chemotherapy as Neoadjuvant Treatment for Advanced Endometrial Cancer : A Prospective, Single-arm, Open-label Clinical Study","Inclusion Criteria:\n\n1. Voluntary participation and signed informed consent form;\n2. Age ≥18 years;\n3. Eastern Cooperative Oncology Group performance status 0-1;\n4. The International Federation of Gynecology and Obstetrics (FIGO 2023) stage III-IVb of endometrial cancer;\n5. Has not received any systematic anti-tumor treatment for advanced diseases in the past;\n6. Have measurable disease according to RECIST v1.1 criteria;\n7. Patients must meet the following criteria for laboratory tests to ensure adequate organ function:\n\n   * ANC ≥1,500\u002Fmm3, or ≥1.5×109\u002FL\n   * Platelet count≥75,000\u002Fmm3 or 75 x 109\u002FL\n   * Hemoglobin≥9 g\u002FdL or ≥5.6 mmol\u002FL\n   * Glomerular filtration rate estimated（eGFR） according to the Chronic Kidney Disease Epidemiology Collaborative Group formula （CKD-EPI EQ6）was≥40 mL\u002F 1.73m2\n   * Serum total bilirubin ≤ 1.5x upper limit of normal range（ULN）\n   * Both AST and ALT were ≤3 x ULN\n8. The expected lifespan exceeds 3 months.\n\nExclusion Criteria:\n\n1. Received PD-1 target therapy other than tislelizumab or other antibody or drug therapy that specifically targets T-cell costimulation or checkpoint channels within 6 months before enrollment；\n2. Has human immunodeficiency virus infection, active viral hepatitis, and active tuberculosis infection；\n3. Active leptomeningeal disease or uncontrolled, untreated brain metastases resulting in elevated intracranial pressure;\n4. Major surgical procedures had been performed within 4 weeks before consent was obtained；\n5. Other conditions deemed by the investigator to be ineligible for enrollment.","FEMALE","18 Years",{"count":89,"type":90},20,"ESTIMATED","INTERVENTIONAL",[93],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of tislelizumab in combination with chemotherapy as a neoadjuvant treatment for advanced endometrial cancer.",[96],"Endometrial Neoplasms",[98,99,19],"Oncology","Endometrial Cancer","NOT_YET_RECRUITING","2024-04-11",{"date":103,"type":104},"2024-04-12","ACTUAL",{"date":106,"type":90},"2024-06-01",{"date":108,"type":90},"2026-06-30",{"name":5,"class":6},3]